Arranta Bio, a contract development and manufacturing organization that focuses on serving companies seeking to develop and commercialize therapies targeting the human microbiome, agreed to acquire Captozyme, a developer of therapeutics using proprietary enzymes. Financial terms were not disclosed. As part of the transaction, Captozyme has spun out its enzyme therapeutic assets into a newly formed biopharmaceutical company, Oxidien Pharmaceuticals, LLC, to continue clinical development under the leadership of Helena Cowley, Captozyme's outgoing CEO. "Having spent ten years developing processes for clients with over 125 bacteria, including difficult to make organisms, I am delighted that our team will now increase our capacity to serve the microbiome sector as part of Arranta, and we will be able to shepherd clients' products through the clinical phases to commercial with our enhanced capabilities," Aaron Cowley, Captozyme's Founder and CTO.